Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Sep;81(3):e41-e43.
doi: 10.1016/j.jinf.2020.06.061. Epub 2020 Jun 27.

Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure

T Ueland  1 , J C Holter  2 , A R Holten  3 , K E Müller  4 , A Lind  5 , G K Bekken  4 , S Dudman  2 , P Aukrust  6 , A M Dyrhol-Riise  7 , L Heggelund  8
Affiliations
Comment

Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure

T Ueland et al. J Infect. 2020 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest None.

Figures

Fig 1
Fig. 1
Inflammatory markers and respiratory failure during COVID-19 disease. A) Circulating markers measured in the study reflecting inflammation in relevant tissues or cells (pulmonary, adipose, cardiac, renal, platelets) or related to function (fibrogenesis, vascular inflammation). The table shows correlations between the P/F ratio and plasma markers during the course of the study. Partial eta2 is shown in unadjusted analysis (but with time as fixed factor) and following adjustment with eGFR and CRP or eGFR and ferritin. B) Spearman correlation between MMP-9 and P/F ratio at different time-points (day 0–2 blue, day 3–5 red, day 7–10 green) during the course of the study. C) Temporal course of MMP-9 during COVID-19 infection according to respiratory failure. Data are presented as back-transformed estimated marginal means with 95% confidence intervals from the mixed model analysis (see statistical methods) and the P-value for the group effect (i.e. respiratory failure) is given on the graph. *p<0.01, **p<0.01, ***p<0.001. SpD, surfactant protein D; PARC/CCL18, pulmonary and activation-regulated chemokine; ST-2, suppression of tumorigenesis-2; Gal-3, Galectin-3 ; sCD40L, soluble CD40 ligand; NAP2/CXCL7, neutrophil activating peptide; NGAL, neutrophil gelatinase-associated lipocalin; vWF, von Willebrand factor; AngP2, angiopoietin 2; PTX-3, pentraxin 3; sTNFR1, soluble tumor necrosis factor receptor type 1; CXCL16, C-X-C Motif Chemokine Ligand 16; VCAM1, vascular cell adhesion molecule 1; GDF-15, growth differentiation factor; POSN, periostin; OPN, osteopontin; MMP-9, matrix metallopeptidase 9; TIMP1, tissue inhibitor of matrix metalloproteinase; YKL-40 also known as chitinase-3-like protein 1. . (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
See this image and copyright information in PMC

Comment on

References

    1. Petrilli C.M., Jones S.A., Yang J. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020 369:m1966. - PMC - PubMed
    1. Ye Q., Wang B., Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect. 2020;80:607–613. - PMC - PubMed
    1. Herold T., Jurinovic V., Arnreich C. Elevated levels of interleukin-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020 - PMC - PubMed
    1. Grifoni E., Valoriani A., Cei F. Interleukin-6 as prognosticator in patients with COVID-19. J Infect. 2020 - PMC - PubMed
    1. George P.M., Wells A.U., Jenkins R.G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med - PMC - PubMed